Key result
RAAS blockers improve arterial fibrosis and endothelial function but fail to fully reverse remodeling.
Why the study?
The study sought to evaluate the protective effects of enalapril on vascular structural remodeling in a rat model of adrenergic stress and the dynamics of structural and functional vascular changes during RAAS blocker therapy in patients with arterial hypertension.
Do renin-angiotensin-aldosterone system blockers (enalapril, perindopril, valsartan) reverse structural and functional vascular remodeling in experimental adrenergic stress and human hyperreninemic arterial hypertension?
Do renin-angiotensin-aldosterone system blockers (enalapril, perindopril, valsartan) reverse structural and functional vascular remodeling in experimental adrenergic stress and human hyperreninemic arterial hypertension?
Although RAAS blockers reduce aortic fibrosis in rats and improve CIMT and endothelial function in hyperreninemic hypertensive patients (with valsartan normalizing EDVD), they do not achieve complete regression of structural vascular remodeling.
Answers are grounded in this paper and cite their sources.
RAAS blockers yield partial vascular improvements without complete remodeling regression; leaves open need for adjunctive strategies in hypertension.
In this article we investigate the protective effects of enalapril on structural remodeling of the aortic and femoral artery walls in a rat model of adrenergic stress (Wistar rats) and examines the dynamics of structural and functional vascular changes during therapy with renin-angiotensin-aldosterone system (RAAS) blockers in patients with arterial hypertension (AH). The experimental results demonstrated that enalapril reduced the development of fibrotic changes in the thoracic and abdominal aortic walls but did not prevent the degradation of elastic fibers in the thoracic aorta. In the abdominal aorta, despite enalapril administration, a further decrease in the volume density of elastin was observed. In the femoral artery wall, enalapril exhibited no protective effect on remodeling whatsoever. The clinical part of the study revealed that in patients with the hyperreninemic form of AH, despite a statistically significant reduction in carotid intima-media thickness (CIMT) and an improvement in endothelium-dependent vasodilation (EDVD) with both perindopril and valsartan, normal EDVD values were achieved only with valsartan therapy. The mean CIMT values in both treatment groups remained above normal levels. Thus, despite positive trends, complete regression of vascular remodeling during RAAS blocker therapy cannot be confirmed.
No takes yet. Share an insight, caveat, or question.
Атаев et al. (2026) studied Arterial hypertension (hyperreninemic form) in humans and adrenergic stress in Wistar rats. RAAS blockers (enalapril in rats; perindopril and valsartan in humans) was evaluated on Structural and functional vascular changes (aortic/femoral fibrosis and elastin density in rats; carotid intima-media thickness [CIMT] and endothelium-dependent vasodilation [EDVD] in humans). RAAS blockers (enalapril, perindopril, valsartan) improved aortic fibrosis, CIMT, and EDVD (normalized only with valsartan), but failed to achieve complete regression of vascular remodeling.
Synapse has enriched 10 related papers. Consider them for comparative context: